What is the difference between tucatinib and neratinib?

Tucatinib and neratinib differ significantly in several aspects.

Tucatinib is an oral, reversible HER2 targeted tyrosine kinase inhibitor (TKI).选择性抑制HER2酶活性，对其他HER家族受体（如EGFR）的抑制作用最小。

Neratinib: is an oral, potent, irreversible tyrosine kinase inhibitor (TKI).靶向HER2、EGFR和HER4，通过阻断泛HER家族及其下游信号通路转导，抑制肿瘤生长和转移。

图卡替尼最初于2020年4月获得美国食品药品监督管理局（FDA）批准，用于治疗HER2阳性的晚期乳腺疾病。 2023Year1Month19Day, FDA批准了图卡替尼联合曲妥珠单抗的新组合疗法，治疗既往治疗过的RAS野生型HER2阳性转移性结直肠疾病。 Recommended dosage and usage should be followed by medical advice.

奈拉替尼2020年4月27日，获得中国国家药品监督管理局（NMPA）批准上市，用于Intensive adjuvant treatment for HER2positive early breast cancer. The recommended dose is 240 mg (6 tablets) taken orally once daily for one year with meals.

Common side effects of tucatinib include diarrhea, palmar and plantar erythema, nausea, hepatotoxicity, vomiting, stomatitis, decreased appetite, anemia, and rash.

Common side effects of neratinib include diarrhea, nausea, vomiting, abdominal pain, fatigue, rash, swelling and stomatitis, increased transaminases, dry skin, etc. Diarrhea is one of the serious adverse reactions of neratinib.

References:

https://www.drugs.com/medical-answers/difference-between-tucatinib-neratinib-3557625/